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Proliferating cells require iron and, therefore, express the transferrin receptor 
(CD71) that mediates cellular iron uptake. Cycling thymocytes, which have the 
CD4-8-3-, CD4-8+3-, or CD4+8+3- phenotypes, also express CD71. The 
importance of CD71-mediated iron uptake for proliferation and maturation of 
thymocytes was studied using fetal thymus organ cultures at day 14 of gestation 
and treating them for 7 days with a CD71 monoclonal antibody (mAb). The 
intracellular iron deficiency caused by this treatment, inhibits both proliferation 
and maturation of the thymocytes. Cell recovery was reduced by 60 % , but cells 
still expanded tenfold during the culture. Remarkably, the final maturation of ap 
T cells was completely blocked as no thymocytes with low or high CD3/a(3TcR 
expression developed. Moreover, only few cells reached the CD4+8+3- stage of 
T cell development. CD4-8-3- thymocytes, however, as well as its CD44-25+ 
subset developed in normal numbers, suggesting that CD44-25+ CD4-8-3- 
cells, or their immediate progeny, were most vulnerable to CD71 mAb treatment. 
The development of y6 T cells,which also express CD71,was not affected in these 
cultures. This suggests that y6 T cells are either less iron-dependent or possess 
alternative iron-uptake mechanisms. Thus, our observations indicate that CD71 
treatment, causing decreased intracellular iron levels, severely inhibits the major 
proliferation phase from the CD44-25+ CD4-8-3- to the CD4+8+3- cells, and 
completely abrogates the final maturation of CD4+8+3- cells into a@TcR- 
expressing cells. In contrast, proliferation and differentiation of the earliest 
thymic precursors into CD44-25+ CD4-8-3- cells is not affected by CD71 
treatment. 
1 Introduction 
The thymus provides a unique environment for the devel- 
opment of T lymphocytes, supporting both precursor cell 
proliferation and maturation [l] .These precursor cells, with 
a CD4-8-3- phenotype, differentiate in the thymus via 
CD4-8+3-, CD4+8+3- and CD4+8+3'oWcells into mature 
CD4+8- and CD4-8+ thymocytes, expressing the 
CD3/apTcR complex at the cell surface [2-61. In addition, 
the CD4-8-3- cells are heterogenous and can be divided 
into three subpopulations on the basis of expression of 
Pgp-1 (CD44) and the p55-chain of the interleukin-2 
receptor (IL-2Ra or CD25): CD44+25- cells develop via 
CD44-25+ into CD44-25- cells [7-91. Within this scheme 
of T cell development, a major expansion phase starts at the 
CD44-25+ CD4-8-3- stage of T cell development. This 
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phase of intense proliferation ends within the CD4+8+3- 
thymocyte subpopulation, indicating that cell division 
ceases before the CDYapTcR complex is expressed on the 
surface of the CD4+8+ thymocyte [3, 10, 111. 
Recently, we observed that this major expansion phase in 
early T cell development is marked by the expression of the 
transferrin receptor (CD71; [12]). Thymocytes with 
CD4-8-3-, CD4-8+3- and CD4+8+3- phenotypes in both 
fetal and adult thymus expressed CD71 [12].These subpo- 
pulations also contain almost all cycling cells present within 
the thymus [3, 5, 8, 10, 131, and through DNA analysis we 
found that CD71 expression on thymocytes is closely 
related to proliferation [12]. 
The transferrin receptor is involved with the uptake of iron 
delivered to the cell by the iron-transporting molecule, 
transferrin [14]. The internalized iron is either stored in 
ferritin deposits or used as a substrate for the biosynthesis 
of iron-containing proteins. Iron uptake by the proliferat- 
ing cell is essential for the iron-containing enzyme ribonu- 
cleotide reductase involved with DNA synthesis 1151. 
However, CD71 is not only expressed by cycling cells, but 
also by cells that require iron for other iron-dependent 
proteins, such as the enzyme peroxidase in monocytes. 
Similarly, the expression of CD71 by thymocytes is proba- 
bly not only related to cell division, but may also reflect the 
use of iron by iron-containing proteins involved with 
maturation of the thymocytes. Therefore, we analyzed the 
role of the transferrin receptor-mediated iron uptake in 
T cell development. By treating fetal thymus organ cultures 
with the CD71 mAb ER-MP21[16] ,we observed that T cell 
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proliferation was severely inhibited. Furthermore, we 
found that crp T cell development was completely abro- 
gated, whereas development of y6 T cells was not affected 
by the treatment. The data presented here indicate that 
CD71 treatment has a major effect on the CD4-8-3- 
t hymocytes. 
2 Materials and methods 
2.1 Mice 
2.4 Antibody blocking 
Day 14 FTOC were treated with purified anti-transferrin 
receptor mAb ER-MP21 [16], in concentrations of 25, 50 
and 100 pg/ml. Subsequent cultures were treated with the 
high dose of 100 pg/ml ER-MP21 only. Control cultures 
received PBS only, or the IgG2a isotype control antibody 
ER-MP20 [23] at a dose of 100 pg/ml. All cultures received 
the same amount of PBS and the contribution of PBS to the 
cultures never exceeded 10 % . In FTOC day 14 + 12, mAb 
containing culture medium was replenished at day 6. 
Fetal (gestational day 14) and adult BALB/c (H-2d) mice 
were bred and maintained in the animal facilities of our 2.5 Immunofluorescence and flow cytometric analysis 
department. 
2.2 Antibodies 
Viable thymocyte suspensions were prepared by disrupting 
four to five lobes in a small volume of PBS containing 0.5 % 
BSA and 2 mM sodium azide in a small potter homogenizer. 
Cells were washed. counted and subseauentlv used for 
analytical flow cytometry. Routinely, 1051 cells kere  incu- 
bated with FITC-, biotin-, or R-phycoerythrin-conjugated 
mAb or an mAb mixture, followed by R-phycoerythrin or 
tricolor-conjugated streptavidin (Caltag, San Francisco, 
CA), as previously described [ 121. For double staining using 
hybridoma supernatant and CD4-R-phycoerythrin, cells 
were successively incubated with supernatant, FITC- 
coniugated anti-rat antiserum, 3 % normal rat serum, and 
The antibodies used in this study are listed in Table 1 
[16-231. They were purified from hybridoma culture super- 
natant by affinity chromatography and conjugated with 
FITC or biotin. The CD4-R-phycoerythrin was commer- 
cially obtained (Becton Dickinson, Mountainview, CA) .To 
avoid aspecific staining, all conjugates were optimally 
titrated. 
Table 1. Characteristics of the monoclonal antibodies 
CDa) Antigen Clone Conjuga- Reference 
tionb) 
CD3 CD3 KT3 
CD4 L3T4 GK1.5 
MT4 H129.19 
CD8 Lyt-2 53-6.7 
CD71 TfR ER-MP21 
TcRl y8TcR GL3 
TcR2 ~ ~ T c R  H57-597 









CD2-R-phycoerythrin. Background fluorescence was de- 
termined by staining cells with streptavidin-fluorochrome 
conjugates only or with the FITC-conjugated mAb ER- 
MP20. 
Analytical flow cytometry was carried out on a FACScan 
(Becton Dickinson). Dead cells were excluded on the basis 
of forward and perpendicular light scatter (for three-color 
staining) or a combination of forward light scatter and 
propidium iodide staining (for two-color staining). 
3 Results 
a) Monoclonal antibodies are ordered by the Cluster of Differen- 
b) mAb were used conjugated with FITC (F), biotin (B), or 
tiation (CD) nomenclature, when possible. 
R-phycoerythrin (PE). 
2.3 Fetal thymus organ culture 
Fetal thymus lobes were placed in organ culture, as 
described by Mandel[24] and Jenkinson [25]. Briefly, four 
to five single thymus lobes were placed on the surface of 
polycarbonate filters (0.8-pm pore size; Poretics, Liver- 
more, CA) supported by 7-mm-thick gelatin foam blocks 
(Upjohn Co., Kalamazoo, MI) in 2 ml of medium in 35-mm 
plastic petri dishes (Falcon; Becton Dickinson, Plymouth, 
GB). The culture medium consisted of Iscove's modified 
Dulbecco's medium containing 25 mM Hepes (GIBCO Life 
Technologies, Ltd, Paisley, GB), supplemented with peni- 
cillin, streptomycin, glutamin and 10 YO FCS (Hyclone, 
Logan, UT), heat inactivated (30 min, 56 "C). The cultures 
were grown at 37°C in a humidified incubator with 8.5 '30 
C 0 2  in air. Gestational day 14 fetal thymuses were cultured 
for 7 days (FTOC day 14 + 7). 
3.1 CD71 expression in fetal thymus organ culture 
Recently, we showed that in vivo CD71 was expressed by 
large, cycling thymocytes with CD4-8-3-, CD4-8+3-, and 
CD4+8+3- phenotypes, during both fetal and adult T cell 
development [12]. In the present study we determined the 
functional relevance of transferrin receptor-mediated iron 
uptake for proliferation and maturation of cells in this early 
phase of T cell development. To that purpose, fetal thy- 
muses of gestational day 14 were cultured in the presence of 
the CD71 mAb ER-MP21. Using other target cells, such 
treatment resulted in growth inhibition of cells caused by 
iron starvation [16,26]. We used FTOC, because (i) this 
system supports normal development of ap and y6 T cells 
[27], and (ii) at the start of the culture, all day 14 fetal 
thymocytes were CD71-expressing CD4-8- cells [12]. 
However, first we established whether in vitro, i.e. during 
7days of normal FTOC, CD71 was expressed by large 
immature thymocytes and was down-regulated when the 
aPTcR became expressed, as we observed in vivo [12]. We 
determined CD71 expression by thymocyte subpopulations 
after triple staining the cells with CD71, CD4 and either 
CD8 (Fig. 1) or the apTcR (data not shown). 




Figure 1. CD71 expression by thymocyte subpopulations in FTOC 
day 14 + 7. Thymocytes were stained with CD71-FITC, CD4- 
R-phycoerythrin, and either CD8-biotin (A-F) or anti-ysTcR- 
biotin (G,H), followed by streptavidin-Tricolor. CD7Usize dot- 
plots are shown for total (B), CD4-8- (C), CD4+8+ (D), CD4-8+ 
(E), and CD4+8- (F) thymocytes. Marker lines separate small 
from large and CD71- from CD71+ cells; relative numbers of cells 
are indicated within the quadrants. These CD4/CD8 subpopula- 
tions were defined by quadrant analysis as indicated in Fig. A. 
yhTcR+ thymocytes were identified as CD4-ysTcR' cells (G) and 
characterized by cell size and CD71 expression (H). 
After 7 days of culture, we found that CD4-8- thymocytes 
developed into CD4+8+, CD4+8- and CD4-8+ cells 
(Fig. 1A). At the same time, CD71 was down-regulated on 
developing small cells (Fig. 1B). Subpopulation analysis 
showed that most CD4-8- thymocytes were large, CD71+ 
cells (Fig. 1C). CD4+8+ thymocytes contained a major 
population of small CD71- cells and a minor population of 
large CD71+ cells (Fig. 1D). The latter population did not 
express the aPTcR, whereas a subset of small CD4+8+ cells 
already did (data not shown). The CD4-8+ thymocytes 
were all large CD71+ cells (Fig. 1E). These cells represent 
the immature CD4-8+3- cells, as mature apTcRhigh 
CD4-8+ cells had not yet developed under the in vitro 
conditions (data not shown; [ 121). The CD4+8- population, 
roughly selected using quadrant analysis (see Fig. lA),  
contained both immature aPTcR- and mature aPTcR+ cells 
(data not shown). The aPTcR+ subset within the CD4+8- 
population does not express CD71 and has small to 
intermediate cell size (Fig. 1F). Most cells of the y6 T cell 
lineage, identified as CD4-y6TcR+ cells, expressed CD71 
and were large in cell size (Fig. lG,H). 
Our data indicate that in FTOC CD71 is expressed on 
immature CD4-8-, CD4-8+3-, and CD4+8+3- blast cells, 
including y6 T cells, as observed in vivo in fetal and adult 
T cell development [12]. 
3.2 Proliferation of thymocytes is inhibited by CD71 
mAb treatment 
Day 14 fetal thymuses were cultured in the presence of 
different doses of purified ER-MP21. We observed that cell 
recovery in such cultures was significantly reduced, as 
= 200,000 thymocytes per thymus lobe were recovered, i .e. 
only half the amount recovered from control cultures 
(Table 2). This reduction of 50 % in cell recovery seemed 
independent of the mAb concentration in the range 
studied. Despite the CD71 treatment, cells still proliferated 
and expanded at least tenfold from the start of the organ 
culture, as day 14 fetal thymus contains only about 20,000 
cells. Thus, CD71 treatment causes an inhibition, but not a 
complete abrogation of cell proliferation in the organ 
cultures. 
Table 2. Inhibition of proliferation in CD71 mAb-treated FTOC 
day 14 + 7 
Treatment Cell 
recovery a) 
PBS 429 _t 65 
ER-MP20, 100 pg/ml 390 t 40 
ER-MP21, 100 pg/ml 171 f 15 (p < 0.0005)b) 
ER-MP21, 50 pg/ml 230 k 28 (p < 0.05) 
ER-MP21, 25 pg/ml 206 f 29 (p < 0.01) 
a) Cell recovery is expressedin cellsflobe ( X  Data represent 
the mean k SEM of four to five experiments. 
b) The cell recovery in ER-MP21 mAb-treated cultures differs 
significantly from the cell recovery in the ER-MP20 mAb- 
treated control cultures. The corresponding probability factors 
are indicated within parentheses. 
The optimal dose of the ER-MP21 mAb for functional 
studies was determined by establishing the dose of ER- 
MP21 mAb that results in complete saturation of CD71 
molecules on the surface of the thymocytes in CD71 
mAb-treated FTOC. The ER-MP21 mAb bound to the 
surface of the thymocyte during treatment was detected 
with a FITC-conjugated anti-rat antiserum using flow 
cytometry. We found that complete saturation was only 
obtained with the high dose of 100 yglml (data not shown). 
Therefore, the dose of 100 pg/ml was used in the remainder 
of this study. 
3.3 Differentiation of apTcR+, but not yGTcR+ 
thymocytes is inhibited by CD71 mAb treatment 
In addition to an effect on T cell proliferation, we also 
anticipated an effect of CD71 treatment on T cell differen- 
tiation, because CD71 is expressed by three immature 
thymocyte subpopulations, linked to each other by a 
proliferation-driven differentiation process. In CD71 mAb- 
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So far, these data indicate that, af~ T cell differentiation is 
severely impaired by CD71 mAb treatment. Indeed, 
CD4+8- apTcRhigh and CD4+8+ ~ ~ T C R ' ~ "  thymocytes, 
identified as CD4+3high and CD4+3'OW cells, respectively 
were completely absent in the CD71 mAb-treated cultures 
(Fig. 3A, B). Remaining CD4+8+ thymocytes were TcR-. 
In contrast, there was a relative increase in the number of 
CD4-3+ thymocytes. As Fig. 3C and D indicate, these cells 
are all y6 T cells. Such a relative increase in the number of 
y6TcR+ thymocytes was observed in three different exper- 
iments (Table 3). Yet, in absolute numbers, the y6TcR+ 
population was similar in size in both CD71 mAb-treated 
and control cultures (Table 3). 
treated cultures, cells were all large in size, whereas control 
cultures contained both small and large cells (Fig. 2A, 
upper panels). When thymocytes were stained simulta- 
neously with CD4 and CD8 mAb, a dramatic inhibition of 
T cell differentiation was observed (Fig. 2A, Zowerpanels). 
CD4+8+ and CD4+8- thymocytes developed in very low 
numbers, causing a substantial (relative) increase in the 
number of CD4-8- thymocytes as compared to the control 
culture. In absolute numbers, CD4+8+ and CD4+8- cells 
were drastically reduced (Fig. 2B). The reduction of the 
CD4+8+ thymocytes was not only caused by the almost 
complete absence of small CD4+8+ cells, but also by a 
reduction in the number of large CD4+8+ cells (data not 
shown). The number of CD4-8+ cells, however, was only 
mildly reduced, whereas more CD4-8- cells were recovered 
from CD71-treated cultures compared to control cultures. 
IL-2R+ cells, representing mainly the CD25+ CD4-8-3- 
thymocytes, were also recovered in slightly increased 
numbers (data not shown). 
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Table 3. Recovery of ysTcR+ thymocytes in CD71 mAb-treated 
FTOC day 14 + 7 
Relative (%) Absolute ( X  10-3/lobe) 
Control + CD71 Control + CD71 
mAb mAb 
Exp. la) 5.2 14.7 13.0 16.2 
Exp. 2 5.4 12.8 26.1 24.6 
Exp. 3 5.7 13.6 26.8 20.6 
a) The relative number of ysTcR+ thymocytes was determined 
from histograms; the absolute recovery was calculated using the 
relative number and total cell recovery of the organ cultures. 
Together these results indicate that (i) T cell differentiation 
in the ap T cell lineage is completely abrogated by CD71 
mAb treatment, (ii) thymocytes of the y6 T cell lineage are 
not affected, and (iii) within the CD4-8- compartment, 
cells seem to develop in normal numbers, at least up to the 
CD25+ stage. 
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Figure 2. Inhibition of T cell development in FTOC day 14 + 7 by 
CD71 treatment. Cells from control and CD71 mAb-treated 
cultures were analyzed for cell size (A) and for CD41CD8 
expression (A,B). Cell size, as measured by forward light scatter, is 
depicted in histograms, showing the relative number of large cells 
(A, the upper panels). For CD4/CD8 phenotyping, cells were 
stained with CD4-biotin and CD8-FITC, followed by streptavidin- 
R-phycoerythrin. Subpopulations were quantified by quadrant 
analysis and relative numbers of cells are indicated in the two-color 
dotplots (A, lower panels). In B the absolute numbers have been 
depicted in a bar graph, with different bar patterns for the control 
and CD71 mAb treated cultures. Bars represent the mean k SEM 
for eight (control) or nine experiments. Differences in cell recovery 
are statisticallv significant for CD4+8+ ( p  = 0) and CD4+8- 
y6TcR 
Figure 3. Inhibition of a@ T cell but not y8 T cell development in 
FTOC day 14 + 7 by CD71 treatment. Thymocytes from the 
control culture (A,C) or the CD71 mAb-treated culture (B,D) were 
stained by successive incubations with, either CD3 (A,B) or 
anti-y6TcR (C,D) supernatant, anti-hamster-FITC (Caltag, San 
Francisco), normal rat serum, and CD4-R-phycoerythrin. Subpo- 
pulations were quantified by window analysis for CD4/CD3 
dotplots (A,B) and by quadrant analysis for CD4/ysTcR dotplots 
(P = O.OOO~) tiiymicytes. (C,D); relative numbkrs of cells are indicated in these dotpfots. 
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3.4 Inhibition of differentiation occurs independently of 
inhibition of proliferation 
The question arises whether the observed inhibition of 
differentiation is a mere consequence of the inhibition of 
proliferation, or whether differentiation itself also requires 
iron uptake by the cells. When inhibition of differentiation 
is a mere consequence of the inhibition of proliferation, it 
may be expected that a CD71 mAb-treated culture and a 
control culture with identical cell number would have the 
same developmental stage. To test this assumption, we 
performed two experiments. In the first experiment, we 
analyzed the cell recovery and the developmental stage of 
the organ cultures through a period from day 3 to day 7 of 
the culture (Fig. 4A). We found that cell number in the 
CD71 mAb-treated cultures increased more slowly with 
culture time, as compared with the control cultures. 
Comparison of the cell recovery shows that the control 
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Figure 4 .  Inhibition of differentiation occurs independent of the 
inhibition of proliferation in CD71-treated FTOC day 14 + 7. In 
A ,  the cell recoveries at days 3 to 7 of the organ culture are shown 
for control and CD71 mAb treated cultures (indicated by bars with 
different bar patterns). Asterisks indicate the samples (of equal 
cell recovery) that were used for two-color staining with CD4 and 
CD8 mAb, presented in B. Cells from the control FTOC at day 4 
and from the CD71 mAb-treated FTOC at day 7 were stained with 
CD4-biotin and CDS-FITC, followed by streptavidin-R-phycoery- 
thrin. Subpopulations were quantified by quadrant analysis; the 
absolute numbers of cells (X  are indicated in the quadrants. 
In  a second experiment, a control FTOC at day 4 was compared to  
a CD71 mAb-treated FTOC at day 12 (C). Cells were stained and 
analyzed as indicated for B. 
culture at day 4 and the CD71 mAb-treated culture at day 7 
contained comparable cell numbers, 164000 and 178000 
cells per lobe, respectively (see asterisks in Fig. 4A). 
Comparison of the developmental stage of the thymocytes 
in these particular samples showed that the CD71 mAb- 
treated culture contained more CD4-8- and CD4-V cells, 
but fewer CD4+8+ cells (Fig. 4B). In addition, cells of the 
CD71 mAb-treated culture were all large in size, whereas 
the control culture also contained small cells (data not 
shown). This observation indicates that cells in CD71 
mAb-treated cultures were generally less mature than cells 
in control cultures. 
In a second experiment, under identical experimental 
conditions, the control culture at day 4 and the CD71 
mAb-treated culture at day 12 contained comparable cell 
numbers (168000 and 181 000 cells per lobe, respectively; 
Fig. 4C). Comparison of the developmental stages of these 
cultures, once more showed that more CD4-8- and 
CD4-8+ cells, but fewer CD4+8+ cells developed after 
CD71 mAb treatment and all cells were large in size (data 
not shown). 
Together, these data suggest that (i) inhibition of differen- 
tiation is not just a consequence of inhibition of prolifera- 
tion, and (ii) that terminal maturation of ap thymocytes 
requires higher intracellular iron levels than proliferation 
only. 
4 Discussion 
Iron is essential to proliferation of cells. Therefore, cells 
express the transferrin receptor (CD71) on the cell surface 
during cell cycle [14]. Recently, we have also shown that 
cycling immature thymocytes are characterized by CD71 
expression [ 121. The importance of intracellular iron levels 
for maturational processes is much less known, however. In 
this study, we determined the importance of CD71 
mediated iron uptake for both proliferation and maturation 
of thymocytes in FTOC. 
Indeed, our data indicate that proliferation of thymocytes 
in FTOC is inhibited by CD71 mAb treatment. However, 
proliferation was only partially inhibited, and the number 
of cells still expanded tenfold from the start of the culture. 
Partial inhibition of proliferation was not caused by 
suboptimal mAb treatment, because all CD71 molecules 
were saturated with the CD71 mAb, even after 7 days of 
organ culture. Rather, this observation indicates that 
thymocytes can still internalize low levels of iron, likely, 
because the CD71 mAb ER-MP21 recognizes an epitope on 
CD71 different from the transferrin-binding site [16]. As a 
consequence, iron-loaded transferrin can still bind to the 
receptor and be internalized. However, for various cell 
types it was found that binding of the CD71 mAb severely 
decreases recycling of CD71 between the cell surface and 
the intracellular compartments and, consequently, renders 
cells iron deficient [ 16,26, 28-30]. Likewise, thymocytes in 
FTOC became iron deficient, but, apparently, the low 
intracellular iron level could still support a low level of 
proliferation. 
A major observation from our study is that the maturation 
of afi T cells, but not y6 T cells, in the FTOC was inhibited 
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CD71 treatment, causing decreased intracellular iron lev- 
els, severely inhibits the major proliferation phase from the 
CD44-25+ CD4-8-3- to the CD4+8+3- cells, and com- 
pletely abrogates the final maturation of CD4+8+3- cells 
into aPTcR-expressing cells. In contrast, proliferation and 
differentiation of the earliest thymic precursors into 
CD44-25+ CD4-8-3- cells is not affected by CD71 
treatment. 
by CD71 mAb treatment. Thymocytes expressing the 
CD3laPTcR complex at low or high level did not develop in 
the CD71 mAb-treated cultures. Similar to proliferation, 
the maturation of the cells was only partially inhibited: a 
small fraction of CD4-8- cells, present in day 14 fetal 
thymus, could still develop into CD4+8+3- cells. Conse- 
quently, it seems that in CD71 mAb-treated cultures, 
thymocytes can only develop to the transition point where 
CD3- cells start to mature into CD3Iow cells. Normally, cell 
division stops at this transition, cells enter the Go phase of 
the cell cycle and become small in size [6, 8, 311. In 
addition, down-regulation of CD71 also marks the transi- 
tion of CD3- to CD3*OW cells [12]. Our present findings 
suggest that maturation of immature aPTcR- thymocytes 
into aPTcR-expressing cells is critically dependent on the 
intracellular iron levels of the maturing thymocytes. 
Despite the development of thymocytes up to the 
CD4+8+3- stage, our data suggest that CD71 treatment 
already affects thymocytes before the CD4+8+3- stage of 
T cell development. This suggestion was supported by the 
observation that all thymocyte subpopulations were severe- 
ly reduced in cell number or even absent,with the exception 
of the CD4-8-3- cells. Additionally, we observed that in 
preliminary experiments using FTOC from day 16 
embryos, proliferation and differentiation of cells were not 
inhibited by CD71 mAb treatment (data not shown). The 
most likely explanation of this preliminary finding is that 
day 16, in contrast to day 14, fetal thymocytes have passed 
the stage most sensitive to CD71 mAb treatment. Since 
day 16 fetal thymus, like day 14 fetal thymus, mainly 
contains CD4-8- thymocytes [12], it seems likely that cells 
most sensitive for CD71 treatment belong to a subset within 
the CD4-8-3- thymocyte subpopulation. 
Subsets of CD4-8-3- cells can be defined by expression of 
CD44 and CD25: CD44+25- cells develop via CD44-25+ 
into CD44-25- cells ([9,32]; unpublished observations). 
Recently, the CD25+ CD4-8-3- stage of adult thymocyte 
differentiation was identified as a possible major branching 
point for the development of the three T cell lineages, i.e. 
the a6 T cells, the y6 T cells and the CD4-8- aP T cells 
[9, 331. The development of the CD25+ CD4-8-3- cells is 
unaffected by CD71 mAb treatment. This is based on the 
observations, that (i) CD44-25+ cells develop in normal 
numbers in CD71 mAb treated cultures, and (ii) y6 T cells, 
developing from the CD25+ cells, are not affected by CD71 
treatment.Together, these data suggest that the CD44-25+ 
CD4-8-3- cells or their immediate progeny, the CD44-25- 
CD4-8-3- cells, are probably most dependent on intracel- 
lular iron levels. 
The development of y6 T cells, that also express CD71 ,was 
not affected by CD71 mAb treatment. This observation 
indicates that, in contrast to maturing ap T cells, y6 T cells 
apparently internalize sufficient amounts of iron to support 
their normal development. Two mechanisms can provide an 
explanation for this difference: (i) y6 T cells internalize 
more iron because, despite CD71 mAb treatment, cells still 
have a high CD71 recycling rate, or (ii) y6 T cells have lower 
iron requirements for differentiation than ap T cells. 
In summary, our results indicate that iron deficiency, caused 
by CD71 mAb treatment, leads to an inhibition of ap T but 
not y6 T cell development. Our observations indicate that 
Iron deficiency, caused by malnutrition, is one of the most 
common health problems in third-world countries, and may 
lead to impaired cell-mediated immunity [34, 351. As our 
data indicate, this may be caused by the inhibition of afi 
T cell development within the thymus [36]. 
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